RNS Number : 2826P
Ovoca Bio PLC
16 February 2021
Ovoca Bio plc
("Ovoca" or the "Company")
Result of Extraordinary General Meeting
Dublin, Ireland, 16 February 2021 - Ovoca Bio plc (LSE: OVB; ISE: OVXA), a biopharmaceutical company with a focus on women's health, announces that each of the resolutions proposed at the Extraordinary General Meeting of the Company, held earlier today, were passed.
The full text of each resolution was included in the Notice of Extraordinary General Meeting of the Company, circulated to shareholders on 25 January 2021. The resolutions relate to the replacement of CREST with Euroclear Bank for electronic settlement of trading in the ordinary shares of the Company.
Voting on the resolutions was conducted by poll, and the details of the poll vote are set out below:
Votes for
%
Votes Against
%
Votes Total
% of ISC Voted
Votes Withheld
Resolution 1: Shareholders Consent to Migration
35,370,233
99.99
1,880
0.01
35,372,113
39.99
0
Resolution 2: Approval and Adoption of New Articles of Association of the Company
35,370,233
99.99
1,880
0.01
35,372,113
39.99
0
Resolution 3: to give effect to aspects of the Migration
35,370,233
99.99
1,880
0.01
35,372,113
39.99
0
Notes
1. Any proxy appointments which gave discretion to the Chair have been included in the "votes for" total.
2. A "Vote Withheld" is not a valid vote in Irish law and was not counted in the calculation of the proportion of the votes "For" or "Against" a resolution.
End
For further information:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
info@ovocabio.com
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
John Frain / Daragh O'Reilly
Tel: +353 1 679 6363
Consilium Strategic Communications
Chris Gardner, Chris Welsh, Carina Jurs
ovocabio@consilium-comms.com
Tel: +44 (0)20 3709 5700
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD).
The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.
Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ROMDZGMZFVDGMZM
